Tempus AI: Less Risky Than When I Said BuySeeking Alpha · 2 days ago
Tempus Expands Strategic Collaboration with Bristol Myers SquibbBusiness Wire · 2 days ago
Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer's Disease and Other Neurological ConditionsBusiness Wire · 2 days ago
Tempus AI: Moderna's New Cancer Vaccine Partner Is The Pick Of The AI Biotech BunchSeeking Alpha · 2 days ago
How Tempus AI Built a Defensible Data Moat in Precision HealthcareETF Trends · 3 days ago
Tempus Presents Data Demonstrating AI-Enabled Pre-Screening Can Help Identify Patients for Biomarker Testing in NSCLCGuruFocus · 5 days agoTempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 30, 2026 | -$0.14 | -$0.04 | Beat |
| May 5, 2026 | -$0.21 | -$0.13 | Beat |
| Feb 24, 2026 | -$0.04 | -$0.04 | Beat |
| Nov 4, 2025 | -$0.17 | -$0.11 | Beat |
| Aug 8, 2025 | -$0.23 | -$0.22 | Beat |
| May 6, 2025 | -$0.26 | -$0.24 | Beat |